MED-COVID-19: Building research infrastructure (Milestone 4.AA)

---

Success Criteria

• At least one study to establish new or leverage existing clinical cohorts for longitudinal prospective studies to examine the impact of COVID-19 on AD/ADRD risk and outcomes.
• Leverage existing resources to ensure brain, other biological samples, and standardized AD/ADRD clinical data from persons infected with SARS-CoV-2, including in populations that are disproportionally impacted, are accessible for AD/ADRD research.

Summary of Key Accomplishments

This milestone has just been initiated. Accomplishments are forthcoming.

The key accomplishments summary is current as of November 2022.

Accomplishments/Implementation Activities

Funding Initiatives

• NOT-AG-21-016: Neurological and Neurocognitive Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration

Research Programs and Resources

• Projects funded in FY22

Research Highlights

• Workshop: Gaps and Opportunities for Real-World Data: Stakeholder Workshop

Relevant Recommendations

• 2022 ADRD Summit: Multiple Etiology Dementias (MED) Special Topic: Impact of COVID-19 on AD/ADRD Risk and Outcomes Milestone 1, Priority 1

Related Milestones